癌症治疗相关的心脏功能障碍,这是由于Panitumumab的结果
Isabelle Senechal1,2,3, Nikolaos Vogiatzakis4, Maria Sol Andres4
1Cardio-Oncology Service, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, UK. isabelle.senechal-dumais.1@ulaval.ca.
Cardio-oncology (London, England)
|April 11, 2024
概括
本病例报告详细介绍了一名患者,他在转移性结直肠癌治疗后患有心力衰竭,排泄率降低. 需要进一步的研究来了解这种不良事件,并指导接受抗EGFR治疗的患者的监测.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕尼图穆马布是一种抗皮肤生长因子受体 (EGFR) 单克隆抗体,用于转移性结直肠癌.
- 心血管不良事件是针对性癌症治疗的一个问题.
- 目前的指导方针缺乏针对抗EGFR抗体治疗的特定心血管监测.
研究的目的:
- 报告一个新发性心力衰竭的新病例,在帕尼图穆马布治疗后减少了喷射分数.
- 调查帕尼图穆马布与心脏功能障碍之间的潜在联系.
- 强调需要在接受抗EGFR抗体治疗的患者中进行心血管监测.
主要方法:
- 对一个患有心力衰竭症状的患者进行了全面的诊断工作.
- 调查包括心声图,心脏MRI,CT冠状动脉图,侵入性冠状动脉图和18F-FDG PET-CT.
- 诊断方法旨在排除心力衰竭的常见原因,如缺血和炎症.
主要成果:
- 一名73岁的男性在服用一次剂量panitumumab后两个月出现了严重的左心室功能障碍 (排泄分数为25%).
- 广泛的调查排除了缺血性心脏病,炎症过程和其他可识别的原因.
- 这代表了第一例报告的心力衰竭与减少的喷射分数与panitumumab相关的情况,深度表型支持.
结论:
- 帕尼图穆马布治疗可能与新发性心力衰竭和减少喷射分数相关.
- 这种心脏不良事件的潜在机制尚不清楚.
- 在等待进一步的数据之前,建议实施类似于EGFR氨酸激酶抑制剂 (如osimertinib) 的心血管监测协议.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.7K
07:29Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
19.6K
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:27Tumor Immunotherapy
522
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
522
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K